-
公开(公告)号：KR100663880B1
公开(公告)日：2007-01-03
申请号：KR1020040009336
申请日：2004-02-12
Applicant: 한국과학기술연구원
Abstract: 본 발명은 유기용매에 녹는 한 가지 이상의 생체적합성 결정성 고분자와 한 가지 이상의 중성지질이 유기용매에 균일하게 용해되어 있고, 0.05 내지 14 중량%의 생체적합성 결정성 고분자, 0.1 내지 14 중량%의 중성지질 및 나머지 분량의 유기용매를 포함하는 고분자-지질 조성물, 상기 고분자-지질 조성물로부터 유기용매 또는 유기용매와 지질을 제거하여 얻어지는 고분자-지질 복합 구조체 또는 고분자 구조체, 및 이들의 제조방법에 관한 것이다.
-
公开(公告)号：KR1020050081092A
公开(公告)日：2005-08-18
申请号：KR1020040009337
申请日：2004-02-12
Applicant: 한국과학기술연구원
IPC: A61K9/107
CPC classification number: A61K9/006 , A61K9/107 , A61K9/1274
Abstract: 본 발명은 생체적합성 고분자를 포함하여 입체적으로 안정화된 상태인 에멀젼 또는 큐보좀 조성물, 이를 포함하는 에멀젼 또는 큐보좀 제형 및 이들의 제조방법에 관한 것이다.
-
公开(公告)号：KR1020050081091A
公开(公告)日：2005-08-18
申请号：KR1020040009336
申请日：2004-02-12
Applicant: 한국과학기술연구원
CPC classification number: A61L27/44 , A61F2013/00089 , A61L15/10 , A61L27/56 , C08L67/04 , C12M3/00
Abstract: 본 발명은 유기용매에 녹는 한 가지 이상의 생체적합성 결정성 고분자와 한 가지 이상의 중성지질이 유기용매에 균일하게 용해되어 있고, 0.05 내지 14 중량%의 생체적합성 결정성 고분자, 0.1 내지 14 중량%의 중성지질 및 나머지 분량의 유기용매를 포함하는 고분자-지질 조성물, 상기 고분자-지질 조성물로부터 유기용매 또는 유기용매와 지질을 제거하여 얻어지는 고분자-지질 복합 구조체 또는 고분자 구조체, 및 이들의 제조방법에 관한 것이다.
-
公开(公告)号：KR100507968B1
公开(公告)日：2005-08-17
申请号：KR1020010049772
申请日：2001-08-18
Applicant: 한국과학기술연구원 , 주식회사 스마트세이프존
IPC: A61K47/48
CPC classification number: A61K31/704 , A61K47/61 , A61K47/6907
Abstract: 본 발명은 자기집합체(self-aggregates)를 형성하는 항암제-키토산 복합체 및 그의 제조방법에 관한 것으로서, 보다 상세하게는 소수성 항암제, 친수성 키토산으로 구성되는 수계에서 자기집합체를 형성하는 항암제-키토산 복합체 및 그의 제조방법에 관한 것이다. 본 발명의 항암제-키토산 복합체는 수계에서 자기집합체를 형성하여 암조직에 대한 선택성이 높을 뿐만 아니라, 약물을 장기간 지속적으로 방출할 수 있고, 또한 자기집합체의 내부에 항암제를 추가적으로 첨가하여 화학적 결합으로 제한되어 있는 약물 함유량을 늘릴 수 있기 때문에 암에 대한 항암화학요법에 유용하게 사용될 수 있다.
-
公开(公告)号：KR100503889B1
公开(公告)日：2005-07-26
申请号：KR1020020042794
申请日：2002-07-20
Applicant: 한국과학기술연구원
IPC: A61K31/245
CPC classification number: A61K9/5078 , A61K9/0095 , A61K9/5026 , A61K9/5031 , A61K31/14 , A61K31/245 , A61K45/06 , A61K2300/00
Abstract: 본 발명은 옥틸로늄 브로마이드의 약물의 세포내 흡수증가를 위한 p-당단백질 저해제로서의 신규한 용도에 관한 것이다. 보다 상세하게, 본 발명은 p-당단백질을 저해함으로써 항암제와 같은 약물과 동시에 또는 약물 투여 전에 경구로 투여 시에 약물의 세포내 흡수율 및 생체내 이용률을 향상시키는 p-당단백질 저해제로서의 옥틸로늄 브로마이드를 제공한다.
-
Patent Agency Ranking
公开(公告)号：KR1020030071373A
公开(公告)日：2003-09-03
申请号：KR1020020011040
申请日：2002-02-28
Applicant: 한국과학기술연구원
IPC: A61K9/107
Abstract: PURPOSE: A process of preparing a fat emulsion using oils having higher specific gravity than water as a fat emulsion base material and amphoteric surfactants as an emulsifier is provided. The fat emulsion exhibits excellent expression efficiency in adhesive cell lines as well as in the presence of serum as compared to conventional liposome or squalane-based fat emulsion formulation and thus permits easy in-vitro assay of gene expression efficiency. CONSTITUTION: A fat emulsion comprises: 2 to 30% by weight of oil mixtures comprising iodized oil and one or more glyceride-based oils such as squalene or squalane as a fat emulsion base; 0.01 to 40% by weight of one or more amphoteric surfactants; 0.01 to 10% by weight of hydrophilic polymers, phospholipid combined with hydrophilic polymers or polymerizable phospholipid; 0.01 to 10% by weight of glycerol, soluble peptide or soluble protein; and the balance comprising water. The oil mixtures contain 40% by weight of iodized oil selected from the group consisting of iodized poppy seed oil.
Abstract translation: 目的：提供使用比水重量大的油作为脂肪乳液基质和作为乳化剂的两性表面活性剂制备脂肪乳剂的方法。 与常规脂质体或基于角鲨烷的脂肪乳剂制剂相比，脂肪乳剂在粘合细胞系以及血清存在下表现出优异的表达效率，因此允许容易的体外测定基因表达效率。 构成：脂肪乳液包含：2至30重量％的包含碘化油和一种或多种甘油酯基油如角鲨烯或角鲨烷作为脂肪乳液基质的油混合物; 0.01〜40重量％的一种或多种两性表面活性剂; 亲水性聚合物0.01〜10重量％，与亲水性聚合物或聚合性磷脂结合的磷脂; 甘油0.01〜10％，可溶性肽或可溶性蛋白质; 余量包括水。 油混合物含有40重量％的选自碘化罂粟籽油的碘化油。
-
27.发明公开폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신 失效溶解氧气表面蛋白的组合物，溶解液体制剂，溶解粉末制剂，其制备及其疫苗
公开(公告)号：KR1020030028672A
公开(公告)日：2003-04-10
申请号：KR1020010059365
申请日：2001-09-25
Applicant: 한국과학기술연구원
IPC: A61K9/10
Abstract: PURPOSE: Provided is a process of preparing a solubilizing composition which is used as an effective vaccine by solubilizing a pneumococcal surface protein A(PspA) as an antigenic protein and stably delivers it to a desired position in the body. Therefore, the composition can be an effective vaccine which induces protective immunity in an infant as well as an adult. CONSTITUTION: The solubilizing composition of PspA contains 0.001 to 2% by weight of PspA as an effective component, 9 to 90% by weight of one or more monogylceride-based compounds, 0.01 to 90% by weight of one or more emulsifiers, 0.01 to 10% by weight of water or an aqueous solution and 0.001 to 5% by weight of an organic solvent.
Abstract translation: 目的：提供一种通过溶解肺炎球菌表面蛋白A（PspA）作为抗原蛋白并稳定地将其递送至体内所需位置而用作有效疫苗的增溶组合物的方法。 因此，组合物可以是在婴儿和成年人中诱导保护性免疫的有效疫苗。 构成：PspA的增溶组合物含有0.001〜2重量％的PspA作为有效成分，9〜90重量％的一种或多种单甘油酯类化合物，0.01〜90重量％的一种或多种乳化剂，0.01〜 10重量％的水或水溶液和0.001〜5重量％的有机溶剂。
-
公开(公告)号：KR100374482B1
公开(公告)日：2003-03-03
申请号：KR1020020005448
申请日：2002-01-30
Applicant: 한국과학기술연구원
IPC: A61K9/10
CPC classification number: A61K9/5123 , A61K9/1075 , A61K9/1272 , A61K48/00 , C12N15/88
Abstract: The present invention relates to oil-in-water lipid emulsions composed of non-triglyceride oils and solid lipid nanoparticles (SLN) composed of triglyceride or ethyl stearate used as gene transfection agents and drug delivery systems and method for preparing thereof. The present invention also concerns the method of transferring genes or drugs efficiently into cells by using the lipid emulsions and solid lipid nanoparticles. Also the present invention relates to the method of preparing lipid emulsions containing lipophilic or amphiphilic drugs by using squalene or squalane as the core-oil. The present invention also concerns the method of preparing the solid lipid nanoparticles containing lipophilic or amphiphilic drugs by using ethyl stearate as the core-fat.
Abstract translation: 本发明涉及由非甘油三酯油和由甘油三酯或硬脂酸乙酯组成的固体脂质纳米粒（SLN）组成的水包油脂质乳剂，其用作基因转染剂和药物递送系统及其制备方法。 本发明还涉及通过使用脂质乳剂和固体脂质纳米粒子将基因或药物有效地转移到细胞中的方法。 本发明还涉及通过使用角鲨烯或角鲨烷作为核心油来制备含有亲脂性或两亲性药物的脂质乳剂的方法。 本发明还涉及通过使用硬脂酸乙酯作为核心脂肪来制备含有亲脂性或两亲性药物的固体脂质纳米粒子的方法。
-
公开(公告)号：KR1020020066778A
公开(公告)日：2002-08-21
申请号：KR1020010007125
申请日：2001-02-13
Applicant: 한국과학기술연구원
IPC: A61K47/44
CPC classification number: A61K9/0014 , A61K9/0019 , A61K47/44
Abstract: PURPOSE: A process of preparing the subject liquid or powder formulation is provided by adding an aqueous solution of poorly absorbable material in the body such as peptide, protein or water-soluble polymer to a mixture of monoglyceride, emulsifiers and organic solvents. Whereby, the formulation can be easily dispersed without addition of mechanical force and does not generate phase separation, hydrolysis and oxidation even when stored for long period time. CONSTITUTION: A composition to promote absorption of a poorly absorbable material in body comprises 9 to 90% by weight of one or more monoglycerides, 0.01 to 90% by weight of one or more emulsifiers, 0.01 to 10% by weight of an aqueous solution having solubility to a poorly absorbable material in body, 0 to 90.9% by weight of an organic solvent and 0 to 5% by weight of an additive. Also it is prepared by dissolving the monoglycerides and emulsifiers in the organic solvent containing the aqueous solution having solubility to a poorly absorbable material in body and removing a volatile organic solvent from the obtained viscose composition. The formulation contains 1 to 99% by weight of the composition and 1 to 99% by weight of an organic solvent.
Abstract translation: 目的：制备本发明液体或粉末制剂的方法是通过将不良吸收材料的水溶液（例如肽，蛋白质或水溶性聚合物）加入到单酸甘油酯，乳化剂和有机溶剂的混合物中来提供的。 因此，即使长期储存，配方也可以容易地分散而不增加机械力，并且不会产生相分离，水解和氧化。 构成：促进吸收体内吸收不良物质的组合物包含9至90重量％的一种或多种甘油单酯，0.01至90重量％的一种或多种乳化剂，0.01至10重量％的含有 对体内难以吸收的材料的溶解度，0-90.9重量％的有机溶剂和0-5重量％的添加剂。 另外，通过将单酸甘油酯和乳化剂溶解在含有对体内吸收不良的材料具有溶解性的水溶液的有机溶剂中，并从得到的粘胶组合物中除去挥发性有机溶剂。 该制剂含有1至99重量％的组合物和1至99重量％的有机溶剂。
-
公开(公告)号：KR1020020033665A
公开(公告)日：2002-05-07
申请号：KR1020020005448
申请日：2002-01-30
Applicant: 한국과학기술연구원
IPC: A61K9/10
CPC classification number: A61K9/5123 , A61K9/1075 , A61K9/1272 , A61K48/00 , C12N15/88
Abstract: PURPOSE: Provided are a solid lipid nanoparticle as a gene or drug carrier, a formulation, and a method for preparing the same, thereby effectively transferring DNAs, bioprobes and drugs to the target cells. CONSTITUTION: The solid lipid nanoparticle comprises: a) at least one solid lipid nanoparticle material selected from C12-18 triglyceride or ethyl stearate, 2-30%; b) at least one kind of emulsifier including cationic surfactants, 0.01-20%; and c) the balance of water.
Abstract translation: 目的：提供作为基因或药物载体的固体脂质纳米颗粒，制剂及其制备方法，从而有效地将DNA，生物探针和药物转移至靶细胞。 构成：固体脂质纳米颗粒包含：a）至少一种选自C12-18甘油三酸酯或硬脂酸乙酯的固体脂质纳米颗粒材料，2-30％; b）至少一种乳化剂，包括阳离子表面活性剂，0.01-20％; 和c）水的平衡。
-
-
-
-
-
-
-
-
-
Search Results
70
records
(took 0.029 seconds)
